Wednesday 16 June 1999
The distinguishing feature of a biotechnology company, as opposed to one of the pharmaceutical giants, is that they are meant to be entrepreneurially led, fleet of foot and confined to the business of drug discovery - costly development, trials and marketing is left largely to the big boys.
One by one, these attributes are being abandoned. The entrepreneurs who founded the biotechs are being thrown overboard, dismissed as "boffins" or worse, ill equipped for the rigours of running a "real" business. Some, most notably British Biotech, have even attempted to make the jump to fully fledged pharmaceutical stock. Before its fall, British Biotech was moving into undertaking its own latter stage clinical trials and had ambitious plans for developing a proprietary marketing network.
Now the sector is catching the consolidation bug too. A recent survey of European biotechnology companies found that a third planned to merge or make an acquisition over the next two years. Does this not rather undermine the raison d'etre of these prospectors of chemical compounds? The potential for cost cutting - the rationale for most big mergers - is presumably limited, while by stifling creativity in size, there is a real danger that mergers will destroy entrepreneurialism.
By combining their science bases, Celltech and Chiroscience hope to increase their chance of breakthrough drug discovery as well as limit the downside of product failures. But this is about the most that can be said for the process. Still, a trend is a trend and investment bankers are already matchmaking with a vengeance. Will British Biotech end up as predator or prey? Its size and cash ought to ensure it is the former, but it is still too weakened by Millargate to guarantee it.
Wellcome Image Awards: The most striking images from the world of science, including breast cancer cells under chemical attack and a photographer’s own kidney stone
Missing Malaysia Airlines plane: Terrorism explanation 'cannot be ruled out', says CIA
Bob Crow death: 'Admired by his members, feared by employers' - Tributes pour in for RMT union leader and 'working class hero' Bob Crow
Oscar Pistorius murder trial: Athlete repeatedly sick as court hears 'graphic details' of Reeva Steenkamp's post-mortem
How climate change helped Genghis Khan: Scientists believe a sudden period of warmer weather allowed the Mongols to invade with such success
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Exclusive: Impact of immigrants on British workers ‘negligible’
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
The quiet diplomat: Catherine Ashton - recognised and admired in all the world’s troubled countries, yet ridiculed at home
Grace Dent: Who cares if she spells it Barraco Barner? Gemma Worrall is more employable than some bookish arts graduate
- 1 Bad cattitude: Family call police after crazed and 'hostile cat with a history of violence' attacks baby before attempting to 'flee custody'
- 2 Family forced to flee home after discovering 'terrifying' nest of spiders in bananas
- 3 First Kiss: Filmmaker gets 20 strangers to make out on YouTube with awkward results
- 4 Grace Dent: Who cares if she spells it Barraco Barner? Gemma Worrall is more employable than some bookish arts graduate
- 5 Bob Crow death: 'Admired by his members, feared by employers' - Tributes pour in for RMT union leader and 'working class hero' Bob Crow
iJobs Money & Business
£1000 per month: Inspiring Interns: The company works with Tier 1 FTSE 100 Ban...
£35000 - £60000 per annum + Bonus + Benefits: Pro-Recruitment Group: You must ...
£60000 - £80000 per annum + BONUS + BENEFITS: Harrington Starr: A top, City ba...
VOLUNTARY ONLY - EXPENSES REIMBURSED : Reach Volunteering: Fantastic opportuni...